• Lutte contre les cancers

  • Qualité de vie, soins de support

  • Oesophage

Long-term quality of life after oesophagectomy with gastric conduit interposition for cancer

Menée aux Pays-Bas par questionnaire auprès de 100 patients ayant survécu à un cancer après avoir subi une œsophagectomie avec rétablissement de la continuité du tube digestif, cette étude transversale analyse leur qualité de vie à long terme (durée médiane de suivi : 36 mois)

Background : Gaining insight in long-term health-related quality of life more than 1 year after oesophagectomy will assist clinical decision-making and inform patients about the long-term consequences of surgery. Methods : In this cross-sectional study, all consecutive patients who underwent oesophageal resection with gastric interposition for cancer at a tertiary referral centre between January 2007 and July 2012 were included. European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 and QLQ-OES18 were sent to all patients alive without recurrence more than 1 year after surgery. Results : The questionnaires were completed by 92 of 100 patients. Median duration of follow-up after surgery at completing the questionnaire was 36 months (range: 12–75). Global quality of life scores were similar to a general population reference group (76 ± 19 versus 78 ± 17; p = 0.26). However, patients scored significantly worse compared to the general population reference group on physical-, role-, cognitive- and social functioning (p < 0.001). Neoadjuvant therapy and minimally invasive oesophagectomy were associated with significantly better health-related quality of life (HRQL) and symptom scores (p < 0.05). Conclusion : Global HRQL more than 1 year after oesophagectomy with gastric tube reconstruction is comparable to the general Dutch background population, while specific functional and symptom scores are significantly worse. Neoadjuvant therapy and minimally invasive surgery are associated with quality of life benefits in long-term survivors.

European Journal of Cancer

Voir le bulletin